These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37410463)

  • 1. Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021.
    Rosic T; Kolla G; Leece P; Kitchen S; Gomes T
    JAMA Netw Open; 2023 Jul; 6(7):e2321947. PubMed ID: 37410463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
    Schmidt RA; Everett K; Perez-Brumer A; Strike C; Rush B; Gomes T
    Addiction; 2024 Jun; 119(6):1111-1122. PubMed ID: 38476027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
    Hu T; McCormack D; Juurlink DN; Campbell TJ; Bayoumi AM; Leece P; Kent JT; Gomes T
    CMAJ; 2023 Dec; 195(49):E1709-E1717. PubMed ID: 38110219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
    Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
    Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
    Bodkin C; Bondy S; Regenstreif L; Kiefer L; Kouyoumdjian F
    BMJ Open; 2021 Nov; 11(11):e048944. PubMed ID: 34794988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Informing youth-centred opioid agonist treatment: Findings from a retrospective chart review of youths' characteristics and patterns of opioid agonist treatment engagement in a novel integrated youth services program.
    McInerney K; Marchand K; Buckley J; Gao C; Kestler A; Mathias S; Argyle A; Barbic S
    Early Interv Psychiatry; 2023 Oct; 17(10):1028-1037. PubMed ID: 37259685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
    Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
    Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
    Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
    Gomes T; Campbell TJ; Martins D; Paterson JM; Robertson L; Juurlink DN; Mamdani M; Glazier RH
    PLoS Med; 2021 Jun; 18(6):e1003631. PubMed ID: 34061846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
    Moallef S; DeBeck K; Fairbairn N; Cui Z; Brar R; Wilson D; Johnson C; Milloy MJ; Hayashi K
    Addict Sci Clin Pract; 2022 Dec; 17(1):73. PubMed ID: 36522789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
    Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
    BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.
    Morin KA; Tatangelo M; Marsh D
    BMJ Open; 2024 Feb; 14(2):e080790. PubMed ID: 38401902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
    Manhapra A; Stefanovics E; Rosenheck R
    Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
    Spithoff S; Meaney C; Urbanoski K; Harrington K; Que B; Kahan M; Leece P; Shehadeh V; Sullivan F
    Can Fam Physician; 2019 Oct; 65(10):e443-e452. PubMed ID: 31604755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.